Abstract: A method for isolating a mammalian genomic DNA replication origin, the method including: isolating the genomic DNA molecules; identifying 500 bp windows within the DNA molecules; isolating from the genomic DNA molecules the fragments that have a size from 500 pb up 6000 pb; selecting a DNA replication origin that is able, when contained in the DNA of an Eukaryotic cell, to produce nascent DNA, and to initiate DNA replication; and isolating the origin.

Abstract: The invention relates to the use of an inhibitor of the activity or stability of the pre-replication complex, also called pre-RC, for the in vitro preparation of haploid eukaryotic somatic cells from eukaryotic somatic diploid cells, said inhibitor completely inhibiting the activity or stability of said pre-RC.

Abstract: The invention relates to a method for initiating the replication of a deoxyribonucleic acid molecule, said method comprising a step of inserting, into said deoxyribonucleic acid molecule, at least one nucleic acid molecule representing a multicellular DNA replication origin, the replication origin comprising at least nine nucleotides, the at least nine nucleotides consisting of at least three uninterrupted origin repeating elements (OGRE).

Abstract: A method for initiating the replication of a deoxyribonucleic acid molecule includes inserting into the DNA at least one nucleic acid molecule representing a multicellular DNA replication origin. The replication origin contains at least nine nucleotides and contains at least three uninterrupted origin repeating elements (ORE), each ORE having the sequence N3GN4, wherein N3 is T or G and N4 is G or C. The method can confer autonomous replication properties to a non-self-replicating DNA molecule. A process for preparing a vector for use in said methods is also presented.

Abstract: The use of a composition including at least one permeabilized nucleus of a first cell, or at least one permeabilized first cell including the nucleus and an extract of female germinal cells, or eggs, of a multicellular organism, the eggs being blocked in the metaphase II of meiosis, the extract including EGTA, for carrying out a method for obtaining pluripotent stem cells, or tissues derived from the pluripotent stem cells, or of cloning, provided that the process is not for cloning human beings.

Abstract: The composition includes either an isolated protein complex including MCM8 and MCM9 proteins, or nucleic acid molecules coding for the proteins that constitute the complex, or compounds inhibiting the formation and/or the stability, or the activity of the complex, for its use for enhancing or reducing animal, preferably mammal, fertility.

Abstract: An isolated antibody specifically binding the C-terminus part of the MCM9 protein, the C-terminus part of the MCM9 protein is one of the following sequences: the amino acids sequence from the position 391 to the position 1143 of the MCM9 proteins of the sequence as set forth in SEQ ID NO: 2 or 16, or the amino acids sequence from the position 391 to the position 1143 of the MCM9 protein of the sequence as set forth in SEQ ID NO: 8.

Abstract: A composition including at least a protein consisting of an amino acid sequence as set forth in SEQ ID NO: 1, or a salt or a solvate thereof, in association with a pharmaceutically acceptable carrier, for its use for treating pathologies link to DNA replication.

Abstract: A method for initiating the replication of a deoxyribonucleic acid molecule includes inserting into the DNA at least one nucleic acid molecule representing a multicellular DNA replication origin. The replication origin contains at least nine nucleotides and contains at least three uninterrupted origin repeating elements (ORE), each ORE having the sequence N3GN4, wherein N3 is T or G and N4 is G or C. The method can confer autonomous replication properties to a non-self-replicating DNA molecule. A process for preparing a vector for use in said methods is also presented.

Abstract: A composition of a female germinal cell (egg) extract of pluricellular organisms in M-phase of the cell cycle, the extract being used for a mitotic remodeling of chromosomes of donor cells of pluricellular organisms, wherein the mitotic remodeling confers to the nucleus of the donor cells the ability to adapt themselves to the early embryonic development, in particular to the replication phases, in order to carry out the embryonic development or to obtain stem cells.

Abstract: A composition of a female germinal cell (egg) extract of pluricellular organisms in M-phase of the cell cycle, the extract being used for a mitotic remodeling of chromosomes of donor cells of pluricellular organisms, wherein the mitotic remodeling confers to the nucleus of the donor cells the ability to adapt themselves to the early embryonic development, in particular to the replication phases, in order to carry out the embryonic development or to obtain stem cells.

Abstract: The composition includes either an isolated protein complex including MCM8 and MCM9 proteins, or nucleic acid molecules coding for the proteins that constitute the complex, or compounds inhibiting the formation and/or the stability, or the activity of the complex, for its use for enhancing or reducing animal, preferably mammal, fertility.

Abstract: The use of a composition including at least one permeabilized nucleus of a first cell, or at least one permeabilized first cell including the nucleus and an extract of female germinal cells, or eggs, of a multicellular organism, the eggs being blocked in the metaphase II of meiosis, the extract including EGTA, for carrying out a method for obtaining pluripotent stem cells, or tissues derived from the pluripotent stem cells, or of cloning, provided that the process is not for cloning human beings.

Abstract: The present invention relates to the use of a female germinal cell (egg) extract of pluricellular organisms in M-phase of the cell cycle for a mitotic remodeling of chromosomes of donor cells of pluricellular organisms, wherein the mitotic remodeling confers to the nucleus of the donor cells the ability to adapt themselves to the early embryonic development, in particular to the replication phases, in order to carry out the embryonic development or to obtain stem cells.

Abstract: An isolated antibody specifically binding the C-terminus part of the MCM9 protein, the C-terminus part of the MCM9 protein is one of the following sequences: the amino acids sequence from the position 391 to the position 1143 of the MCM9 proteins of the sequence as set forth in SEQ ID NO: 2 or 16, or the amino acids sequence from the position 391 to the position 1143 of the MCM9 protein of the sequence as set forth in SEQ ID NO: 8.

Abstract: The use of the human or animal MCM9 gene, or parts of the gene, or transcripts thereof, or antisense nucleic acids able to hybridize with part of the gene or transcripts, or silencing RNA derived from parts of the transcripts and able to repress the MCM9 gene, or proteins or peptidic fragments translated from the transcripts, or antibodies directed against the proteins or peptidic fragments, for the preparation of a pharmaceutical composition for the treatment of a human or animal pathology linked to a dysfunction of the expression of the MCM9 gene, or of human or animal cancers.

Abstract: The present invention relates to the use of purified nascent DNA for the implementation of a process allowing the mapping and the numbering of the active DNA replication origins of multi cellular eukaryotic cells, and the characterisation of the sequence of the replication origins.

Abstract: The use of the human or animal MCM9 gene, or parts of the gene, or transcripts thereof, or antisense nucleic acids able to hybridize with part of the gene or transcripts, or silencing RNA derived from parts of the transcripts and able to repress the MCM9 gene, or proteins or peptidic fragments translated from the transcripts, or antibodies directed against the proteins or peptidic fragments, for the preparation of a pharmaceutical composition for the treatment of a human or animal pathology linked to a dysfunction of the expression of the MCM9 gene, or of human or animal cancers.

Abstract: The present invention relates to the use of a peptidic sequence which comprises or is constituted of a peptidic chain of at least contiguous amino acids selected from the amino acid sequence SEQ ID NO: 4, SEQ ID NO: 4 being delimited by the amino acid in position 76 and by the amino acid in position 160 of SEQ ID NO: 2 (human Geminin), provided that, if present, the flanking regions of the peptidic chain in the peptidic sequence are different from the flanking regions of the peptidic chain in SEQ ID NO: 2, for the preparation of a drug intended for the treatment or prevention of pathologies implying pathological DNA replication and/or differentiation disorders, or disturbance of the cellular proliferation/differentiation balance.